PATENT CLAIM ANALYSIS

Application Number: 16121198
Application Type: Utility
Filing Date: 2018-09
Publication Date: 2019-03
Patent Classification: ["514", "211150"]

Abstract:
Disclosed herein are compounds which inhibit the kinase activity of dual leucine zipper (DLK) kinase (MAP3K12), pharmaceutical compositions, and methods of treatment of DLK-mediated diseases, such as neurological diseases that result from traumatic injury to central nervous system and peripheral nervous system neurons (e.g. stroke, traumatic brain injury, spinal cord injury), or that result from a chronic neurodegenerative condition (e.g. Alzheimer's disease, frontotemporal dementia, Parkinson's disease, Huntington's disease, amyotrophic lateral sclerosis, spinocerebellar ataxia, progressive supranuclear palsy, Lewy body disease, Kennedy's disease, and other related conditions), from neuropathies resulting from neurological damage (chemotherapy-induced peripheral neuropathy, diabetic neuropathy, and related conditions) and from cognitive disorders caused by pharmacological intervention (e.g. chemotherapy induced cognitive disorder, also known as chemobrain).

Claim (Index 69):
The method of  claim 68 , wherein R 5  is selected from methyl and trifluoromethyl.

Metadata:
- Claim Count in Document: 137.0
- Percentile: 97.0
- Lexical Diversity: 1.74157
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['15836442', '15199100', '15631417', '11942480', '16035310']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7764472475803618
- 35 USC 102 Novelty (BERT): 0.5183357456098667
- Combined Prediction Score: 0.7506360973833123
- Mean Citation Score: 246.423266
- Max Citation Score: 310.2461
- Similarity Product: 229.253401236558

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 0
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test